Bolt Biotherapeutics, Inc.

BOLT Healthcare Biotechnology

In the quarter to June 2026, revenue fell 99.7%, EPS fell 2.47%, free cash flow grew 38.9% and total debt fell 14.3%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

4.06 0.18 −4.25%
Market cap
$8.2M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
4/9
Altman Z
−12.67
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
35.61 30.26 25.75 20.56
Total non-current assets
29.45 26.49 22.28 19.78
Total Assets
65.05 56.75 48.03 40.34
Total current liabilities
9.97 8.44 7.34 7.87
Total non-current liabilities
22.99 21.81 20.86 19.84
Total liabilities
32.95 30.24 28.21 27.70
Common Equity (Total)
32.10 26.51 19.82 12.64
Shareholders Equity (Total)
32.10 26.51 19.82 12.64
Total Debt
20.89 20.13 19.35 18.53

Show all line items

In millions of $ except per-share values · columns are period end dates